ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Non-Coding Transcripts From Diversified Members of IgLec Family Protect Antiviral Effectors From Viral miRNA.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Immune gene families frequently produce numerous non-coding transcripts, yet their biological functions remain largely unexplored. Here, using the arthropod immunoglobulin domain-containing lectin (IgLec) family as a paradigm, we provide evidence that this complexity may reflect a critical defensive function for non-coding transcripts in antiviral immunity. IgLec is restricted to decapod infraorders (Brachyura and Astacidea), and a structurally related bacterial homolog suggests its origin may involve horizontal gene transfer. The IgLec family generates extraordinary transcript diversity through three mechanisms, multi-locus duplication, inter-locus recombination, and extensive alternative splicing, yielding both protein-coding and non-coding transcripts. Protein-coding IgLec variants restrict viral replication by inducing antimicrobial peptide expression. Upon white spot syndrome virus infection, non-coding transcripts (e.g., intron-retaining transcripts) are preferentially targeted by virus-encoded microRNA-N48, thereby protecting protein-coding isoforms from repression. Loss of these decoy transcripts compromises antiviral defense and increases host mortality. Collectively, these results reveal a decoy-based antiviral strategy in which non-coding transcripts safeguard immune effectors from pathogen subversion, uncovering an unrecognized layer of innate immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.